Literature DB >> 33830472

CircRNA_OTUD7A upregulates FOXP1 expression to facilitate the progression of diffuse large B-cell lymphoma via acting as a sponge of miR-431-5p.

Wei Liu1, Lei Lei2, Xiaoying Liu2, Suiyan Ye3.   

Abstract

BACKGROUND: A growing number of studies have shown that circular RNA (circRNA) is an important regulator molecule in cancer progression, but it has been poorly studied in diffuse large b-cell lymphoma (DLBCL).
OBJECTIVE: This study aimed to explore the role of circ_OTUD7A in DLBCL.
METHODS: Relative expression levels of circ_OTUD7A, microRNA (miR)-431-5p and forkhead box P1 (FOXP1) were determined by quantitative real-time PCR (qRT-PCR). The proliferation of cells was elevated by colony formation assay and MTT assay. Western blot (WB) analysis was employed to measure the protein levels of proliferation marker, epithelial-mesenchymal transition (EMT) markers, cyclin marker, apoptosis markers and FOXP1. Moreover, the apoptosis, cell cycle process, migration and invasion of cells were detected using flow cytometry and transwell assay, respectively. In addition, the interaction between miR-431-5p and circ_OTUD7A or FOXP1 was confirmed by dual-luciferase reporter assay.
RESULTS: Circ_OTUD7A was highly expressed in DLBCL, and its knockdown could inhibit DLBCL cell proliferation and metastasis, while promote cell cycle arrest and apoptosis. Similarly, FOXP1 also was upregulated in DLBCL, and its silencing could restrain the progression of DLBCL cells. Further experiments revealed that circ_OTUD7A could sponge miR-431-5p and miR-431-5p could target FOXP1. MiR-431-5p inhibitor could reverse the suppressive effect of circ_OTUD7A silencing on DLBCL progression, and FOXP1 overexpression also could reverse the inhibitory effect of miR-431-5p mimic on DLBCL progression.
CONCLUSION: Circ_OTUD7A promoted the progression of DLBCL by regulating the miR-431-5p/FOXP1 axis, which suggested that circ_OTUD7A might function as an oncogene in DLBCL.

Entities:  

Keywords:  Circ_OTUD7A; Diffuse large B-cell lymphoma; FOXP1; miR-431-5p

Mesh:

Substances:

Year:  2021        PMID: 33830472     DOI: 10.1007/s13258-021-01094-z

Source DB:  PubMed          Journal:  Genes Genomics        ISSN: 1976-9571            Impact factor:   1.839


  4 in total

1.  Circ_0001742 promotes tongue squamous cell carcinoma progression via miR-431-5p/ATF3 axis.

Authors:  Y-T Hu; X-X Li; L-W Zeng
Journal:  Eur Rev Med Pharmacol Sci       Date:  2019-12       Impact factor: 3.507

2.  MicroRNA-152 inhibits ovarian cancer cell proliferation and migration and may infer improved outcomes in ovarian cancer through targeting FOXP1.

Authors:  Wen Qin; Wei Xie; Qinglin He; Tianwei Sun; Chaoguo Meng; Kunling Yang; Yuanfu Luo; Dongmei Yang
Journal:  Exp Ther Med       Date:  2017-11-17       Impact factor: 2.447

3.  Comprehensive circular RNA profiling reveals the regulatory role of the circRNA-000911/miR-449a pathway in breast carcinogenesis.

Authors:  Honglei Wang; Yi Xiao; Li Wu; Dachang Ma
Journal:  Int J Oncol       Date:  2018-02-05       Impact factor: 5.650

4.  Expression of Foxp3 and interleukin-7 receptor and clinicopathological characteristics of patients with diffuse large B-cell lymphoma.

Authors:  Yan Zhao; Wen-Li Cui; Zhi-Yin Feng; Jing Xue; Abulajiang Gulinaer; Wei Zhang
Journal:  Oncol Lett       Date:  2020-02-06       Impact factor: 2.967

  4 in total
  3 in total

Review 1.  Roles of circRNAs in hematological malignancies.

Authors:  Fahua Deng; Chengsi Zhang; Tingting Lu; Ezhong Joshua Liao; Hai Huang; Sixi Wei
Journal:  Biomark Res       Date:  2022-07-15

Review 2.  The emerging role non-coding RNAs in B cell-related disorders.

Authors:  Soudeh Ghafouri-Fard; Tayyebeh Khoshbakht; Bashdar Mahmud Hussen; Mohammad Taheri; Elena Jamali
Journal:  Cancer Cell Int       Date:  2022-02-22       Impact factor: 5.722

Review 3.  Emerging Role and Mechanism of circRNAs in Pediatric Malignant Solid Tumors.

Authors:  Qiyang Shen; Xingyu Liu; Wei Li; Xu Zhao; Tao Li; Kai Zhou; Jianfeng Zhou
Journal:  Front Genet       Date:  2022-01-18       Impact factor: 4.599

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.